Transforming Health Care Through Research and Innovation
Transforming Health Care Through Research and Innovation
From innovations in lifesaving TeleNICU care to transformational neurosurgery techniques, Children’s Health is a recognized leader in pioneering pediatric health care.
Since 1961, Children’s Health has been the primary pediatric clinical partner for UT Southwestern, one of the nation’s leading medical education and biomedical research institutions.
As the only academically affiliated pediatric hospital in the North Texas region, Children’s Health offers unparalleled access to the latest groundbreaking research, clinical trials and academic expertise. Together, Children’s Health and UT Southwestern are developing the next-generation of therapies and techniques that will be used to help children across the nation -- and around the world.
Led by faculty from UT Southwestern, the research at Children’s Health seeks to find better cures and treatments for children. With a spirit of innovation and dedication to excellence, our research team translates findings into cutting-edge patient care. With interdisciplinary collaboration, our research touches lives across our many specialties.
U.S. News & World Report Webinar
Register for the upcoming webinar on March 28th from noon to 1pm featuring Dr. Madsen where he, alongside other panelists, will cover The Future of Pediatric Cardiology and how practitioners are working to coordinate care for kids with other complex comorbidities, follow the impacts of interventions well into adulthood and enlist families and community partners in delivering the best possible outcomes and quality of life. This webinar is part of Transforming Pediatric Healthcare, a virtual event series from U.S. News & World Report, developed with support from Children’s Health and its flagship hospital, Children's Medical Center Dallas.
Research Focus Areas
Featured Research Articles
Featured Clinical Trials
-
Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
The purpose of this research study is to make 131I-MIBG therapy available to patients with advanced neuroblastoma, pheochromocytoma, or paraganglioma and further assess the side effects of 131I-MIBG therapy.
-
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA)
The purpose of the study is to assess the efficacy and safety of tisagenlecleucel in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). For pediatric patients who have r/r B-NHL, survival rates are dismal, only ~20-50% subjects are alive at 2 years with overall response rate (ORR) of 20-30% after conventional salvage chemotherapy.
Pediatric Insights Podcast
Pediatric Insights is a medical podcast that will explore the latest in pediatric care and research. Experts from Children’s Health will discuss advances and innovations as they encounter some of the most complex pediatric conditions.
Listen now
Children's Medical Center
Research Institute at UT Southwestern
Established in 2011, Children’s Medical Center Research Institute (CRI) combines the clinical expertise of Children’s Medical Center Dallas with the scientific excellence of UT Southwestern. With research efforts focused on regenerative medicine, cancer biology and metabolism, CRI is making groundbreaking advances in science and medicine.
